ImmunityBio (FRA:26CA) Change In Receivables : €-15.63 Mil (TTM As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is ImmunityBio Change In Receivables?

ImmunityBio's change in receivables for the quarter that ended in Mar. 2025 was €-13.57 Mil. It means ImmunityBio's Accounts Receivable increased by €13.57 Mil from Dec. 2024 to Mar. 2025 .

ImmunityBio's change in receivables for the fiscal year that ended in Dec. 2024 was €-2.25 Mil. It means ImmunityBio's Accounts Receivable increased by €2.25 Mil from Dec. 2023 to Dec. 2024 .

ImmunityBio's Accounts Receivable for the quarter that ended in Mar. 2025 was €15.75 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. ImmunityBio's Days Sales Outstanding for the three months ended in Mar. 2025 was 94.08.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. ImmunityBio's liquidation value for the three months ended in Mar. 2025 was €-754.48 Mil.

ImmunityBio Change In Receivables Historical Data

The historical data trend for ImmunityBio's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunityBio Change In Receivables Chart

ImmunityBio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-2.25

ImmunityBio Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															-	-0.96	-2.83	1.73	-13.57

ImmunityBio Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-15.63 Mil.

ImmunityBio (FRA:26CA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

ImmunityBio's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	15.752	/	15.278	*	91
=	94.08

2. In Ben Graham's calculation of liquidation value, ImmunityBio's accounts receivable are only considered to be worth 75% of book value:

ImmunityBio's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	56.972	-	827.173	+	0.75 * 15.752	+	0.5 * 7.811
=	-754.48

ImmunityBio Change In Receivables Related Terms

Thank you for viewing the detailed overview of ImmunityBio's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunityBio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (FRA:26CA) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

IBRX:USA

Address

3530 John Hopkins Court, San Diego, CA, USA, 92121

Website

https://www.immunitybio.com

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

ImmunityBio Headlines

No Headlines